Nuclear Medicine
MIBG 131 WITHOUT CARRIER (R&D)
Name:
MIBG 131 without carrier (R&D)
Active Principle:
Iobenguan 131I
Therapeutic Action:
It is a radioactive therapeutic agent indicated for the treatment of adult and pediatric patients 12 years of age and older with iobenguane-positive, unresectable, locally advanced or metastatic pheochromocytoma or paraganglioma who require systemic antineoplastic therapy.
Nuclear Medicine
MIBG 131 WITHOUT CARRIER (R&D)
Name:
MIBG 131 without carrier (R&D)
Active Principle:
Iobenguan 131I
Therapeutic Action:
It is a radioactive therapeutic agent indicated for the treatment of adult and pediatric patients 12 years of age and older with iobenguane-positive, unresectable, locally advanced or metastatic pheochromocytoma or paraganglioma who require systemic antineoplastic therapy.
RELATED PRODUCTS
-
177Lu DOTATATE (I+D)
177Lu DOTATATE (I+D)It is a radiolabeled somatostatin analog indicated for: - The treatment of gastroenteropancreatic tumors positive for the somatostatin receptor. Neuroendocrine tumors (GEP-NETs), including the foregut... -
TECHNETIUM GENERATOR
TECHNETIUM GENERATORIt is indicated for obtaining a solution of Sodium Pertechnetate (Tc99m) ... -
IODOSOL 123I (R&D)
IODOSOL 123I (R&D)Sodium iodide (123I) solution is indicated as a diagnostic agent to evaluate thyroid function and/or morphology by scintigraphy and radioactive iodine uptake test. -
AV45 (R+D)
AV45 (R+D)It is indicated for estimating the density of β-amyloid neuritic plaque in the brain of adult patients with cognitive impairment who are being evaluated for Alzheimer's disease and other causes of cognitive...